Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | Sacituzumab tirumotecan (SKB264/MK-2870) - (OptiTROP-Breast01) | Locally recurrent or metastatic triple-negative breast cancer (TNBC) | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (KeyVibe-010) | Resected high-risk melanoma (Stage IIB-IV) | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA versus chemotherapy - (KEYNOTE-B21) | High-Risk Endometrial Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | V116 - (STRIDE-10) | Pneumococcal vaccine | Phase 3 | Data Released | Intramuscular | Immunology |
| Merck & Company Inc. | MK-1084 with KEYTRUDA (pembrolizumab) | Metastatic Non-Small Cell Lung Cancer | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA + LYNPARZA - (KEYLYNK-006) | Metastatic nonsquamous non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous and oral | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) - (LEAP-001) | Advanced or recurrent endometrial carcinoma | Phase 3 | Data Released | Intravenous and oral | Oncology |
| Merck & Company Inc. | KEYTRUDA + LYNPARZA - (KEYLYNK-008) | Metastatic squamous non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous and oral | Oncology |
